ClinicalTrials.gg
CompletedNCT03721328Updated Jan 11, 2022Results posted

Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation

A Phase 2 interventional study of vancomycin hydrochloride and tobramycin sulfate in Prosthetic Joint Infection, sponsored by Osteal Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Osteal Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Study Type

Prospective, single-arm, open-label, multicenter (3 to 5 sites), interventional trial.

Primary Study Objective

The objective of the study is to determine the safety profile of local antibiotic irrigation for the treatment of PJI.

Primary Outcome Measure

The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.

Follow-up

Patients will be assessed for all measures at 3 weeks, 6 weeks, 12 weeks, and 12 months from initial surgery.

02

Conditions studied

  • Prosthetic Joint Infection

Keywords

  • Hip
  • Knee
  • Biofilm
  • Minimum-biofilm-eradication-concentration
03

In context

Lead sponsor

Osteal Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years or greater
  • Preoperative diagnosis of PJI of the hip or knee per the 2018 Definition of Periprosthetic Hip and Knee Infection
  • Chronic PJI (symptoms lasting at least 4 weeks) per Tsukayama et al.
  • Medical clearance for surgery
  • Physical and mental ability and willingness to comply with the protocol, including the ability to read and complete required forms, and willingness and ability to adhere to the scheduled follow-up visits and requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Late acute hematogenous infection per Tsukayama et al.
  • Patients for whom a two-stage exchange arthroplasty is not indicated
  • Sepsis
  • Previously failed single- or two-stage revision arthroplasty for PJI (aseptic revision, polyethylene liner exchange, and/or irrigation and debridement with component retention is allowed)
  • Patients with PJI of more than one joint
  • Patients on chronic antibiotic therapy (≥ 6 months duration)
  • Patients who require therapeutic anticoagulation
  • Patients on antiplatelet therapy for whom withholding antiplatelet therapy for any amount of time is
  • Patients with renal insufficiency/failure (serum creatinine ≥ 2.0 mg/dl)
  • Patients with uncontrolled diabetes, defined as: levels > 8.0%
  • Patients on therapy, chemotherapy for malignant disease, or therapy (e.g. prednisone ≥ 10 mg/day).
  • Patients with immunodeficiency (e.g., splenectomy; sickle cell anemia; Stage 3 ; primary humoral, bone marrow, or other transplantation.)
  • Anticipated or potential patient relocation that may interfere with follow-up examinations
  • Allergy to vancomycin HCl or tobramycin sulfate (Note: prior history of Red Man's syndrome is not considered an allergy)
  • Patients who are pregnant or planning to become pregnant
  • Patients in whom negative pressure wound therapy is contraindicated
  • Patients infected with pathogens that are not considered susceptible to vancomycin HCl or tobramycin sulfate, as per the Investigator's opinion
  • Breastfeeding at screening visit
  • Patients who are prisoners
  • Participation in another clinical trial of another Drug or Investigational Device within the past 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Experimental

    Joint irrigation with vancomycin and tobramycin

    Combination Product: vancomycin hydrochloride and tobramycin sulfate

Interventions

  • Combination productvancomycin hydrochloride and tobramycin sulfate

    Drug pages: Vancomycin · Tobramycin

    vancomycin hydrochloride and tobramycin sulfate via local irrigation

06

What researchers measure

Primary outcomes

  1. Safety Evaluations: Number and Frequency of Adverse Events Among Participants

    The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.

    Time frame: 12 months

07

Results

Posted Dec 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneLocal Irrigation With Vancomycin + Tobramycin
Started15
Completed15
Not completed0

Outcome measures

PrimarySafety Evaluations: Number and Frequency of Adverse Events Among Participants

The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.

Time frame:
12 months
Reported as:
Count of participants · Participants
Safety Evaluations: Number and Frequency of Adverse Events Among Participants
ParticipantsExperimental
Any Adverse Event14
AE Relationship to NPWT Device UNRELATED14
AE Relationship to Study Medication UNRELATED14
AE Relationship to Study Treatment Procedure UNRELATED14
Severity - Mild14
Severity - Moderate7
Severity - Severe6
Serious Adverse Event7
SAE Relationship to NPWT Device UNRELATED7
SAE Relationship to Study Medication UNRELATED7
SAE Relationship to Study Treatment Procedure UNRELATED7
Suspected Adverse Reaction0
Adverse Reactions0

Adverse events

Collected over 12 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Local Irrigation With Vancomycin + Tobramycin0/15 (0%)7/15 (46.7%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventLocal Irrigation With Vancomycin + Tobramycin
Chest painCardiac disorders2/15
Atrial FlutterCardiac disorders1/15
Cardiac failure congestiveCardiac disorders1/15
Pulmonary oedemaCardiac disorders1/15
Dental cariesGastrointestinal disorders1/15
PneumoniaInfections and infestations1/15
Rotavirus infectionInfections and infestations1/15
SepsisInfections and infestations1/15
Avulsion fractureInjury, poisoning and procedural complications1/15
FallInjury, poisoning and procedural complications1/15
Most frequent other events
Showing 10 of 56
Most frequent other events
EventLocal Irrigation With Vancomycin + Tobramycin
Anaemia postoperativeInjury, poisoning and procedural complications8/15
Peripheral swellingGeneral disorders5/15
HypotensionVascular disorders4/15
PyrexiaGeneral disorders2/15
CystitisInfections and infestations2/15
PneumoniaInfections and infestations2/15
FallInjury, poisoning and procedural complications2/15
ArthralgiaMusculoskeletal and connective tissue disorders2/15
Back painMusculoskeletal and connective tissue disorders2/15
Urinary retentionRenal and urinary disorders2/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Experimental
Mean69.27 ± 7.329
Age, Customized
Age, Customized(Participants)Experimental
<60 years2
>= 60 years13
Sex: Female, Male
Sex: Female, Male(Participants)Experimental
Female9
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental
Black or African American1
White14
Region of Enrollment
Region of Enrollment(participants)Experimental
United States15
Affected Joint
Affected Joint(Participants)Experimental
Knee14
Hip1
08

Study locations

4 sites
  • Covenant Hospital
    Saginaw, Michigan 48604, United States
  • Ortho Carolina Research Institute
    Charlotte, North Carolina 28207, United States
  • SSM Health Bone and Joint Hospital at St. Anthony
    Oklahoma City, Oklahoma 73103, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Aug 2020, 21 months.

Results were first posted in Dec 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Oct 26, 2018
StartActual
Oct 26, 2018
Primary completionActual
Aug 25, 2020
CompletionActual
Aug 25, 2020
Results first posted
Dec 9, 2021
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03721328
Lead sponsor
Osteal Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Oct 26, 2018
Primary completion
Aug 25, 2020
Completion
Aug 25, 2020
Results posted
Dec 9, 2021
Last update
Jan 11, 2022

Study contacts

Bryan Springer, MD
principal investigator · Ortho Carolina Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vancomycin · Tobramycin

Start the discussion